Using AI on Kidney Scans to Predict Outcomes After Surgery
Studies whether AI analysis of scans predicts outcomes in adults with kidney cancer.
Key facts
- Who runs it
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Where
- Wuhan, ChinaSee the site
- Trial code
- Registry title
- Application of Radiomics-based AI Models in Predicting Clinical Outcome of Patients With Renal Cell Carcinoma After Surgical Treatment
- Status
- Recruiting
- People taking part
- 400 people, planned
- Started
- Aug 2025
- Planned end
- Aug 2026
- Type of study
- Observational
- Record updated
- 12 August 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults treated for renal cell carcinoma (kidney cancer) at Wuhan Union Hospital. It uses CT scans and AI models to predict outcomes after surgery.
- Age
- Older than 18 years
- Sex
- All sexes can join
- Disease stage
- Renal cell carcinoma confirmed by a tissue biopsy examination
- Earlier treatment
- Treated for renal cell carcinoma at Wuhan Union Hospital from August 2025 to August 2026
- Biomarker or test result
- At least one abdominal CT scan before treatment
Main reasons for not taking part
- Poor image quality
- Incomplete clinical data or loss of follow-up
- Another primary cancer besides renal cell carcinoma
- Unclear pathological diagnosis
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Patients were treated for renal cell carcinoma in Wuhan Union Hospital from August 2025 to August 2026
- Aged > 18 years old
- At least one abdominal CT scan before treatment
- Tissue biopsy pathological examination confirmed the diagnosis of renal cell carcinoma
Who cannot take part
- Presence of another primary malignancy other than renal cell carcinoma
- Poor image quality
- Incomplete clinical data or loss of follow-up
- Unclear pathological diagnosis
Where in China
- Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaContact: Lian YangTaking people
About the trial
What the trial wants to find out
This is a prospective observational cohort study (AI-Kidney-Prognosis), aiming to non-invasively predict the clinical outcomes in renal cell carcinoma patients after surgical treatment using radiomics-based AI models, thereby assisting clinical decision-making and personalized follow-up strategies.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Application of Radiomics-based AI Models in Predicting Clinical Outcome of Patients With Renal Cell Carcinoma After Surgical Treatment (AI-Kidney-Prognosis)
- Plain-language title
- Using AI on Kidney Scans to Predict Outcomes After SurgeryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 12 August 2025